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Hepatitis E virus (HEV) seroprevalences of 0.3%–53% were
reported from industrialized countries. Because these esti-
mates may be inﬂuenced by detection assays, this study
compares 3 frequently used tests for HEV detection: the
MP Diagnostics HEV immunoglobulin G (IgG) enzyme-
linked immunosorbent assay (ELISA), the AxiomDiagnostics
HEV IgG enzyme immunoassay (EIA), and the Mikrogen
recomLine HEV IgG assay. Sera from 200 healthy healthcare
workers and 30 individuals with acute HEV infection were
analyzed. Among the healthy individuals, HEV IgG was
found in 4.5% by the MP Diagnostics assay, in 29.5% by the
Axiom Diagnostics assay, and in 18% by the Mikrogen
assay. Among individuals with acute HEV infection, posi-
tive results were obtained for 83.3%, 100%, and 96.7%, re-
spectively. Thus, the 3 assays show clear differences in
diagnostic sensitivity.
Keywords. Hepatitis E; HEV; anti-HEV IgG; seropreva-
lence; serology; diagnostic sensitivity; commercial assays; acute
infection; southeastern Germany.
Hepatitis E virus (HEV) is a small, nonenveloped RNA virus.
Analysis of viral genomes led to the identiﬁcation of 4 mam-
malian HEV genotypes with distinct geographic distributions
[1]. The virus was ﬁrst postulated in 1980 as causative agent of
enterically transmitted non-A, non-B hepatitis in India and was
identiﬁed 3 years later. In the following years, genotype 1 HEV
was, in many developing countries, identiﬁed as a major cause
of infectious hepatitis transmitted by the fecal-oral route [1].
In recent years, studies have documented that HEV infec-
tion also occurs among individuals in industrialized countries
with no history of travel to HEV-endemic areas [2–4]. Because
viral isolates from these cases were almost identical to strains
detected in swine and wild boars, zoonotic sources of infection
are suspected [5–7]. In Germany, the majority of HEV strains
isolated from patients with acute hepatitis E were genotype 3
[4, 7].
Prevalence estimates for HEV antibodies in different Euro-
pean populations range from 0.3% to 52.5%. Low seropreva-
lences (<4%) were reported from Greece, the Netherlands,
Italy, and northern France, whereas high seroprevalences
(>16%) were reported from the United Kingdom, Denmark,
Moldova, and southwest France [8]. This high variability is
likely attributable to the cultural background and dietary
habits of the study population. However, the diagnostic sensi-
tivity of the HEV antibody assays used in different studies
might also inﬂuence the results and, possibly, be the most im-
portant cause for the striking differences.
This study investigates whether different detection assays
yield different estimates of HEV antibody prevalence. We
compared 3 commercially available HEV immunoglobulin G
(IgG) assays by analyzing sera from healthy healthcare
workers in southeastern Germany. We further determined
how the assays performed in the detection of acute hepatitis E
by analyzing specimens from 30 individuals who were poly-
merase chain reaction (PCR) positive for HEV.
METHODS
Sample Collection
Serum samples were collected during routine daily operations
of our diagnostic laboratory in 2010. Most specimens were
pseudonymized sera collected from healthy healthcare workers
at the University Hospital of Regensburg during their routine
appointment with the company medical ofﬁcer. A total of 200
samples were analyzed: 100 were from males, and 100 were
from females. All subjects resided in southeastern Germany;
29 were aged 15–24 years, 39 were aged 25–34 years, 46 were
aged 35–44 years, 48 were aged 45–54 years, and 38 were aged
55–65 years. Thirty samples from patients with acute hepatitis
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E were also tested; 23 patients were male, 7 were female, and
the median age was 43 years (range, 12–75 years). Acute hepa-
titis E was diagnosed on the basis of clinical symptoms and/or
serological ﬁndings (ie, detection of anti-HEV immunoglobu-
lin M [IgM]). Laboratories used the following screening assays
to diagnose acute hepatitis E: the recomLine HEV immunoblot
(Mikrogen; Neuried, Germany), in 54% of cases; the recom-
Well HEV enzyme-linked immunosorbent assay (ELISA;
Mikrogen), in 23%; and an HEV ELISA (MP Diagnostics; Ill-
kirch, France), in 23%. All cases were conﬁrmed by quantita-
tive reverse transcription PCR in our laboratory, as described
previously [4, 7]. HEV genotype 3 was detected in 23 patients,
and HEV genotype 1 was detected in 3; the HEV genotype in
4 was unknown. Additional details about patients with acute
hepatitis E can be found in Supplementary Table 3.
Characteristics of Anti-HEV IgG Assays
Serum samples were tested for HEV IgG antibodies, using the
following 3 commercially available immunoassays: the MP Di-
agnostics HEV IgG ELISA (developed by Genelabs Technolo-
gies; Singapore), the Axiom Diagnostics (Worms, Germany)
HEV IgG EIA (developed by Wantai; Beijing, China), and the
recomLine HEV IgG immunoblot, denoted hereafter as assay
A, assay B, and assay C, respectively. All assays were per-
formed according to the manufacturer’s instructions. In brief,
for each ELISA measurement, a signal-to-cutoff ratio (SCR)
was calculated by dividing the optical density (OD) by the re-
spective cutoff OD. A negative result was recorded for SCRs of
<0.9, a borderline result was recorded for SCRs of 0.9–1.1, and
a positive result was recorded for SCRs of >1.1. These criteria
were used for assays A and B to achieve better comparability.
Assay C is based on 7 recombinant antigens of HEV genotypes
1 and 3. Stained test strips were scanned with the recomScan
analysis software (Mikrogen). Each antigen band with an in-
tensity greater than or equal to the cutoff was assigned a pre-
deﬁned point value. The ﬁnal results were classiﬁed into 3
categories: negative, deﬁned as ≤2 points; borderline, deﬁned
as 3 points; and positive, deﬁned as ≥4 points.
RESULTS
Samples From Healthy Healthcare Workers
All 200 samples from the healthy healthcare workers under-
went analysis by each anti-HEV IgG assay. Nine samples
(4.5%) yielded positive results by assay A, compared with 59
(29.5%) by assay B and 36 (18%) by assay C. Thus, the overall
seroprevalence suggested by assay B was >6.5 times higher
than that suggested by assay A. Borderline results were yielded
in 3 cases (1.5%) by assays A and B and in 5 cases (2.5%) by
assay C. With all assays, there was a trend of increasing sero-
prevalence with age (Supplementary Figure 1). Positive results
were yielded for 7 samples (3.5%) by all assays, for 29 (14.5%)
by assays B and C only, and for 22 (11.0%) by assay B only
(Supplementary Table 2). Analysis of the distribution of
results demonstrated that the 7 samples positive in all assays
were from a subset of 36 samples that were positive by assay C
(Figure 1). These 36 samples were from a subset of 59 samples
that were positive by assay B (Figure 1). Negative results in all
assays were found for 132 samples (66%).
The correlation of SCRs for each assay combination is
shown in Figure 2. There was little correlation between SCRs
in assays A and B (Figure 2A). Similarly, there was little corre-
lation between SCRs in assay A and points in assays C
(Figure 2B). A roughly better correlation was found between
points in assay C and SCRs in assay B (Figure 2C).
Samples From Individuals With Acute Hepatitis E
Thirty sera from patients with acute hepatitis E were analyzed
by each anti-HEV IgG assay. A total of 25 samples (83.3%)
were positive by assay A, compared with 30 (100%) by assay B
and 29 (96.7%) by assay C. Borderline results were yielded in
2 cases (6.7%) by assay A. Positive results were yielded for 25
samples (83.3%) by all assays, for 2 (6.7%) by assays B and C
only, and for 1 (3.3%) by assay B only (Supplementary
Table 2). There was good correlation between SCRs in assays
A and B (Figure 2D). However, correlation was lower between
points and SCRs in the remaining assay comparisons
(Figure 2E and 2F).
Sera from this group were retested with the IgM versions of
assay B and C. Because some samples were depleted, results
for only 28 specimens (for assay B) and 29 specimens (for
assay C) were available. All 28 specimens (100%) tested by the
IgM version of assay B were positive, whereas 25 of 29
(86.2%) tested by the IgM version of assay C were positive; 4
Figure 1. Schematic distribution of positive results generated with the
MP Diagnostics hepatitis E virus (HEV) immunoglobulin G (IgG) enzyme-
linked immunosorbent assay (A), the Axiom Diagnostics HEV IgG enzyme
immunoassay (B), and the Mikrogen recomLine HEV IgG assay (C ). Bor-
derline results are ignored (ie, rated negative). aContains 8 samples with
borderline results. bOne sample had a borderline result of assay C. cOne
sample had a borderline result of assay A.
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of 29 specimens (13.8%) tested by this version of assay C had
borderline results. The 5 sera (16.7%) that were negative or of
borderline positivity for HEV IgG by at least 1 of the 3 assays
were positive by the IgM version of assays B and C.
DISCUSSION
This study shows signiﬁcant differences in diagnostic sensitivi-
ties of 3 commercially available anti-HEV IgG assays. When
these assays are used in seroprevalence studies, they may lead
to dramatic differences in the estimated percentage of anti-
HEV–positive individuals in a population.
In our study, we analyzed sera from 200 healthy healthcare
workers from the University Hospital of Regensburg and 30
sera from individuals with acute hepatitis E. In the population
of healthcare workers, we found 4.5%, 18.0%, and 29.5% to be
positive for anti-HEV IgG by assays A, C, and B, respectively.
In a ﬁrst attempt at an explanation of these discrepant
results, one might assume that low speciﬁcities of assays C
and B yielded the higher positive rates. However, an analysis
of the results demonstrated that 7 of the 9 samples positive by
assay A were a subset of the 36 sera positive by assay C, the
latter in turn being a subset of the 59 samples positive by
assay B. Random results due to a lack of speciﬁcity would not
show such a pattern (at least not for assays A and C). For this
phenomenon, a difference in diagnostic sensitivity is the most
possible explanation. The ﬁndings in sera from patients with
acute hepatitis E point in the same direction. Here, the 3
assays showed more or less comparable results, with 83.3%,
96.7%, and 100% of specimens testing positive by assays A, C,
and B, respectively. These ﬁndings are consistent with the
ability of less sensitive assays to detect the high antibody con-
centrations during the acute phase of HEV infection.
The seroprevalence found with assay B is in line with data
from a study conducted with >4000 sera from a representative
sample of the German general population [9]. However, many
HEV seroprevalence studies performed in industrialized coun-
tries show signiﬁcant differences [8]. Rates range from 0.3%
(for assay A) in Greece [10] to 52.5% (for assay B) in an
HEV-hyperendemic region in southwest France [11]. Our
results suggest that different HEV antibody detection assays
strongly affect these seroprevalence estimates. This is in line
with data from 2 recently published studies. Bendall et al ana-
lyzed 500 sera from blood donors in the United Kingdom by
means of assays A and B [8]. The authors reported a seropre-
valence of 3.6% by assay A, compared with 16.2% by assay B,
which is surprisingly similar to the ﬁgures we found. More-
over, a literature review by the same authors showed that low
Figure 2. Relationship of signal-to-cutoff ratios (SCRs) and total points among the MP Diagnostics hepatitis E virus (HEV) immunoglobulin G (IgG)
enzyme-linked immunosorbent assay, the Axiom Diagnostics HEV IgG enzyme immunoassay, and the Mikrogen recomLine HEV IgG assay. Broken lines
indicate the borderline regions (0.9–1.1 SCRs for ELISAs and 3 points for the immunoblot) between negative results (<0.9 SCR and ≤2 points, respec-
tively) and positive results (>1.1 SCR and ≥4 points, respectively).
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HEV prevalences (<5%) in developed countries have mostly
been obtained with insensitive assays [8]. In this context,
Mansuy et al repeated a study on the anti-HEV IgG seropreva-
lence among approximately 500 blood donors in southwestern
France [11]. The authors reported that 52.5% of sera tested
positive by assay B, suggesting that HEV is hyperendemic in
the Midi-Pyrénées region. Interestingly, in a previous study
from the same region, the authors used assay A and found
that only 16.6% of specimens were positive [12]. These dis-
crepancies demonstrate the need for validation of antibody
assays against sera from individuals with proven HEV geno-
type 3 infection. Only a few conclusive validation studies have
been published so far [8, 13].
In contrast to the high HEV seroprevalence found in our
study, there was a surprisingly low incidence of hepatitis E in
Germany in 2010 (0.3 cases/100 000). A likely explanation is
that most autochthonous HEV infections are either asymp-
tomatic or unrecognized [14].
In conclusion, our study shows that differences in the sensi-
tivities of anti-HEV IgG tests must be taken into account
when interpreting published HEV seroprevalences, because es-
timates differ signiﬁcantly, depending on the assay used.
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